{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"4"}],"units":"Participants"}],"description":"ORR is presented in this outcome measure as number of responders. Responders were those who had complete response, partial response. Lymphomas evaluated include Non-Hodgkin's Lymphoma. Clinical endpoints and response criteria in mycosis fungoides and Sezary syndrome (Olsen et al., 2011).","groups":[{"description":"Participants with relapsed or refractory CTCL received TTI-621 0.5 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG000","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 0.5 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 0.7 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG001","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 0.7 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 1.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG002","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 1.4 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG003","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 2.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG004","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 2.0 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received a 2.0 mg/kg TTI-621 infusion once every 2 weeks until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG005","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) Q2W / 2.0 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis population included all the participants who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"From first dose of study till the progressive disease/death or withdrawal (maximum observation 6 years 10 months)","title":"Part 4: Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Participants"}